Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03131453 · ClinicalTrials.gov registry record · Phase 2
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1,145
- Enrollment target
NCT03131453 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 1,145 participants.
The verdict
NCT03131453, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1,145 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.
Interventions
- OTHER Matching placebo
- DRUG CNP520 50mg
- DRUG CNP520 15mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,145 participants |
| Start Date | 2017-08-03 |
| Est. Completion | 2020-03-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03131453
The ClinicalTrials.gov registry entry for NCT03131453 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1,145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Matching placebo is the first listed.
NCT03131453 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03131453 about?
NCT03131453 is a clinical study titled "A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease". The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.
What is the current status of trial NCT03131453?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1,145 participants. The study started on 2017-08-03. Estimated completion is 2020-03-26.
What interventions are being tested in trial NCT03131453?
The interventions under investigation include: Matching placebo (OTHER), CNP520 50mg (DRUG), CNP520 15mg (DRUG).
Who is sponsoring clinical trial NCT03131453?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.